The cost of CAR T-cell therapy in Europe varies significantly depending on the country, healthcare system, and the specific treatment used. Generally, CAR T-cell therapies are among the most expensive treatments available, reflecting their advanced technology and the complexity of their development and administration. In Europe, two of the most commonly used CAR T-cell therapies are Kymriah and Yescarta, each designed for different types of blood cancers.
In countries like Germany, France, and the United Kingdom, the cost of CAR T-cell therapy can range from €300,000 to €350,000 per treatment. This price can vary based on the specific healthcare system's negotiation with pharmaceutical companies. For instance, in the United Kingdom, the National Health Service (NHS) negotiates the price of these therapies, which can lead to some variation in cost. In Germany, statutory health insurance typically covers the cost of these treatments, but the exact amount paid by the health system can differ based on negotiations.
It's important to note that these costs often cover more than just the CAR T-cell therapy itself. They include the entire treatment process, which involves the collection of a patient's cells, the modification of these cells in the laboratory, and the subsequent reinfusion into the patient.
Additionally, the price can encompass the necessary hospital stays, pre-treatment conditioning chemotherapy, and the management of potential side effects. Some European countries may have different approaches to financing these treatments, either through national healthcare systems, private insurance, or out-of-pocket payments by patients, which can also affect the overall cost faced by the patient.
Therefore, while the therapy itself has a high price tag, the actual cost to the patient can vary greatly depending on several factors, including the healthcare system and insurance coverage in their respective country.
Israel offers several good options for CAR-T therapy for lymphoma, leukemia, and multiple myeloma. Find out the cost in Israel.
Testimonial by a CAR-T patient at Hadassah hospital
My Husband and I engaged with Tanya Preminger from IHA to travel from New Zealand to Israel for undertaking Car T treatment. During the preparation stage Tanya was very professional in her approach and extremely responsive to our many emails. During our 8 week stay in Israel Tanya was incredibly supportive on both a practical and social level. Tanya was an effective communicator with ourselves and the Hadassah hospital staff, always accountable and flexible with our needs. We would highly recommend Tanya as a representative for other clients who may be considering various treatments in Israel.
Yvonne and Mike Hogan, New Zealand, 8/5/2023
One more patient completed CAR-T cell therapy for blood cancer ( June 2024).
With Dr. Marcus at Sheba hospital, celebrating cancer-free PET CT. (2024)
